Mobile Stroke Units: Does Bringing the CT to the Patient Help

The short answer#

For patients who qualify for clot-dissolving drugs, bringing the CT scanner to the patient does appear to help. A mobile stroke unit is a specially built ambulance that carries a CT scanner, a small point-of-care laboratory, and a crew trained to start thrombolytic medication at the roadside. In two large studies, that arrangement cut the time from stroke onset to treatment by roughly half an hour and raised the odds of walking away with little or no lasting disability. The 2026 American Heart Association and American Stroke Association guideline responded by giving these units its strongest possible rating for eligible patients where a unit already runs. The part the evidence has not settled is money and geography: whether the model is affordable, and whether it can reach the places that arguably need it most.

Key points#

• A mobile stroke unit is an ambulance with an onboard CT scanner and the ability to begin clot-dissolving treatment before reaching the hospital.
• Two 2021 studies, one in the United States and one in Germany, both showed faster treatment and better 90-day recovery.
• The 2026 AHA and ASA guideline gives these units a Class 1, Level A recommendation, its top tier.
• That endorsement applies to eligible patients served by an existing unit; it is not a statement that every region should build one.
• The unresolved issues are high cost and thin evidence in rural areas.

Two different questions hiding in one#

It helps to separate two questions that often get blurred together. The first is clinical: if you are having a stroke, does care aboard one of these units produce a better outcome than a standard ambulance? The second is about policy: given a fixed budget, should a city or region invest in one? The evidence answers the first question clearly and the second question barely at all. Keeping them apart is the single most useful habit you can bring to a headline about this technology.

Why the clock drives everything#

Most strokes are ischemic, meaning a clot has blocked an artery and the downstream brain tissue is starving. Neurons in the affected zone die at a staggering rate while flow is cut off, which is why clinicians describe the emergency in terms of time rather than severity alone. The frontline treatment is intravenous thrombolysis, a drug that breaks the clot apart, and its benefit fades steadily with each minute of delay.

A mobile stroke unit attacks that delay directly. Ordinarily two decisive steps, confirming the diagnosis and starting the drug, wait until the patient reaches a hospital. The unit relocates both onto the road. The onboard CT scan is there to rule out a brain bleed, the one finding that makes thrombolysis dangerous and must be excluded first. Once bleeding is off the table, the crew can give the drug where you are lying instead of after a handoff in the emergency department. The medication itself is identical to what a hospital gives. The only thing that changes is how quickly it arrives.

What the trials found#

The 2026 guideline leans on two studies published in 2021.

BEST-MSU, reported in the New England Journal of Medicine, compared mobile-unit care with conventional emergency medical services across several U.S. cities. Rather than randomizing individual patients, it alternated weeks in which a unit was or was not dispatched. Among patients eligible for the thrombolytic tPA, the median time from onset to treatment was 72 minutes with a mobile unit versus 108 minutes with a standard ambulance. Almost every eligible mobile-unit patient actually received the drug, 97.1 percent against 79.5 percent. At 90 days, more patients in the mobile-unit group had reached a modified Rankin Scale score of 0 or 1, meaning no symptoms or no meaningful disability, at 55.0 percent versus 44.4 percent. Death at 90 days was numerically lower with the units, 8.9 percent versus 11.9 percent, and faster treatment did not appear to trade off against safety.

B_PROUD, run in Berlin and published in JAMA, pointed the same way. This prospective, nonrandomized study compared outcomes when a mobile unit was dispatched against those when a conventional ambulance responded. It found a favorable shift across the entire distribution of disability scores at three months, not only among the patients who did best. Two health systems on two continents landing on the same benefit is the kind of agreement that pushes a recommendation to the top evidence tier.

What the top rating does and does not claim#

A Class 1, Level A recommendation is the strongest a guideline offers: a clear benefit backed by high-quality evidence from more than one study. The scope, though, deserves care. The benefit was shown in patients eligible for thrombolysis who were reached by a unit that already existed. The guideline endorses using a mobile stroke unit over conventional services where one is available. That last clause carries the weight, because availability is precisely what the trials cannot speak to. Saying a tool works when it is present is not the same as saying every community should acquire one.

The cost and access questions left open#

These units are expensive. The trials were not built to measure cost, but separate reporting and modeling put the figures on the order of several hundred thousand to about a million dollars to launch, with a comparable annual sum to operate, reflecting the onboard scanner, the staffing, and the upkeep. Economic models suggest the units can be cost-effective, yet that conclusion depends heavily on setting. The favorable math shows up in dense urban catchments where a single unit reaches enough eligible strokes each year to earn back its fixed cost. Unsurprisingly, that is where most of the trial evidence and most of the working units sit.

That concentration is the heart of the equity problem. Rural regions, where transport times run longest and a scanner on wheels could in theory matter most, are the least studied and the hardest to serve, because sparse populations mean each unit treats fewer patients for the same standing cost. There is a genuine risk that a technology validated in cities widens rather than narrows the urban to rural gap if it is deployed wherever it is easiest to fund. Trial populations also underrepresent some groups, so how well the benefit carries across the full range of communities remains an open question rather than a settled one.

How to read the endorsement#

The honest summary is that the "does it help" question and the "should we build them everywhere" question have different answers. On the first, the evidence is now strong: for the right patient, in a place where a unit is running, moving the CT to the patient shortens the path to treatment and improves recovery, and the 2026 guideline reflects that. On the second, the answer is local. Whether your city should invest turns on its stroke volume, its current transport times, and how a new unit would change access for the people served worst today, not best. A guideline can confirm that a tool works. It cannot judge, from a distance, whether it is the right use of your community's finite resources.